3TR ICS COPD
Research type
Research Study
Full title
Molecular signatures associated with response to ICS treatment in patients with COPD stratified by eosinophil levels
IRAS ID
1009565
Contact name
Lydia Finney
Contact email
Sponsor organisation
Fundació de Recerca Clínic Barcelona-Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Eudract number
2023-505245-13
Clinicaltrials.gov Identifier
Research summary
This study focuses on understanding how inhaled corticosteroids (ICS) affect individuals with chronic obstructive pulmonary disease (COPD). COPD is a condition where the airways in the lungs become inflamed and narrowed, making it difficult to breathe. Patients with COPD may experience exacerbations, or worsening of symptoms, and ICS are often recommended for those who have frequent exacerbations despite using other inhalers. However, not all patients benefit from ICS, and recent research suggests that the number of eosinophils, a type of white blood cells, in the blood might predict the effectiveness of ICS treatment.
The main objective of this study is to explore how ICS affects the proteins and bacteria in the airways of COPD patients and how it influences various signalling pathways in their blood. By understanding these effects, we hope to explain why some people respond well to ICS while others do not, which could lead to more personalised treatment approaches for COPD.
REC name
North West - Liverpool Central Research Ethics Committee
REC reference
24/NW/0375
Date of REC Opinion
8 Apr 2025
REC opinion
Further Information Favourable Opinion